

Office of Pharmacy Services Prior Authorization Criteria

Votrient (pazopanib)

Votrient will be approved for:

1. Diagnosis of *advanced renal cell carcinoma

*Cancer has started to spread.

©2011, Glaxo Smith Kline. All rights reserved.

Revised: October 2011

VTR:3MG 21